An ongoing global pandemic of viral pneumonia (coronavirus disease [COVID-19]), due to
the virus SARS-CoV-2, has infected millions of people and remains a threat to many more …

There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a
significant coagulopathy, a phenomenon termed “COVID-19 associated coagulopathy.” …

Since the onset of the global pandemic in early 2020, coronavirus disease 2019 (COVID-19)
has posed a multitude of challenges to health care systems worldwide. In order to combat …

Since the first description of COVID-19 infection, among clinical manifestations of the
disease, including fever, dyspnea, cough, and fatigue, it was observed a high incidence of …

Coronavirus disease of 2019 (COVID-19) is the clinical manifestation of the respiratory
infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While …

The Covid-19 pandemic has introduced an array of organspecific and systemic phenotypes-
some previously observed in viral infections, including severe acute respiratory syndrome …

Abstract Introduction Coronavirus 2 (CoV-2) infection or coronavirus disease 2019 (COVID-
19) is frequently associated with microvascular thrombosis. The microthrombosis in COVID …

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently
found to suffer from both arterial and venous thrombotic events due to the perpetuation of a …

Although thrombosis frequently occurs in infectious diseases, the coagulopathy associated
with COVID-19 has unique characteristics. Compared with bacterial sepsis, COVID-19 …

Thrombotic complications of the novel coronavirus (COVID-19) are a concerning aspect of
the disease, due to the high incidence in critically ill patients and poor clinical outcomes …